Sign up United Kingdom
ImmuPharma PLC (LON:IMM)

ImmuPharma PLC (LON:IMM)


Share Price
11.45 p
Change
0.1775 (1.57 %)
Market Cap
£15.97 m
Proactive Investors - Run By Investors For Investors

ImmuPharma PLC RNS Release

Lupuzor Pivotal Phase III Study Update


RNS Number : 6822I
Immupharma PLC
23 March 2018
 

                                                                                                                                                                      23 March 2018

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

Lupuzor™ Pivotal Phase III Study Update

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces  that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor™ pivotal Phase III trial study, that 'database lock' is expected on 6 April 2018, with top line results announced by mid-April 2018.

Lupuzor™ is the Company's lead programme for the potential breakthrough compound for Lupus, a life threatening autoimmune disease.

Commenting on the trial update, Tim McCarthy, Chairman, said: "With the continued robust safety record of Lupuzor™ achieved over this trial, we look forward with confidence to reporting top line results in the near future."

For more information on the trial please visit: https://clinicaltrials.gov/ct2/show/NCT02504645

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.com)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

 

Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

 

 

Northland Capital Partners Limited

David Hignell, Dugald Carlean, Jamie Spotswood, Corporate Finance

Rob Rees, Corporate Broking

 

 

                                                  

+44 (0)20 3861 6625

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKBDDCBKDNNB

ImmuPharma PLC Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use